Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated…


- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 -

Read more:
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated...

Related Posts